Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification

American Journal of Gastroenterology

Volumn 108, Issue 5, 2013, Pages 767-774

  Vakil, Nimish ^a   Halling, Katarina ^b   Ohlsson, Lis ^b   Wernersson, Börje ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISTRESS SYNDROME; DYSPEPSIA; ENDOSCOPY; EPIGASTRIC PAIN; EXPLORATORY RESEARCH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PEPTIC ULCER; PH; POSTPRANDIAL DISTRESS SYNDROME; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REFLUX DISEASE QUESTIONNAIRE; REFLUX ESOPHAGITIS; ROME III CLASSIFICATION; SYMPTOM;

ABDOMINAL PAIN; ADULT; AGED; CAPSULE ENDOSCOPY; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREDICTIVE VALUE OF TESTS; SYNDROME;

EID: 84877585940     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.89     Document Type: Article

References (16)

1. Drossman DA . The functional gastrointestinal disorders and the Rome III process . Gastroenterology 2006; 130: 1377-90.
2. Ohara S, Kawano T, Kusano M et al. Survey on the prevalence of GERD and FD based on the Montreal defi nition and the Rome III criteria among patients presenting wiThepigastric symptoms in Japan . J Gastroenterol 2011; 46: 603-11.
3. Talley NJ, Stanghellini V, Heading RC et al. Functional gastroduodenal disorders . Gut 1999; 45 (Suppl 2): II37-42.
4. Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
5. Karamanolis G, Caenepeel P, Arts J et al. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia . Gastroenterology 2006; 130: 296-303.
6. Veldhuyzen van Zanten S, Armstrong D, Barkun A et al. Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confi rmatory acid suppression test (CAST) study: further psychometric validation of the Refl ux Disease Questionnaire . Aliment Pharmacol Ther 2007; 25: 1087-97.
7. Tack J, Caenepeel P, Arts J et al. Prevalence of acid refl ux in functional dyspepsia and its association with symptom profi le . Gut 2005; 54: 1370-6.
8. Xiao YL, Peng S, Tao J et al. Prevalence and symptom pattern of pathologic esophageal acid refl ux in patients with functional dyspepsia based on the Rome III criteria . Am J Gastroenterol 2010; 105: 2626-31.
9. Dent J, Vakil N, Jones R et al. Accuracy of the diagnosis of GERD by physicians, questionnaire and a trial of proton pump inhibitor therapy: the Diamond Study . Gut 2010; 59: 714-21.
10. Shaw M, Dent J, Beebe T et al. The refl ux disease questionnaire: a measure for assessment of treatment response in clinical trials . Health Qual Life Outcomes 2008; 6: 31-6.
11. Shaw MJ, Talley NJ, Beebe TJ et al. Initial validation of a diagnostic questionnaire for gastroesophageal refl ux disease . Am J Gastroenterol 2001; 96: 52-7.
12. Weusten BL, Roelofs JM, Akkermans LM et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data . Gastroenterology 1994; 107: 1741-5.
13. Vakil N, Veldhuyzen van Zanten S, Kahrilas P et al. The Montreal defi nition and classifi cation of gastro-esophageal refl ux disease (GERD)-a global evidence-based consensus . Am J Gastroenterol 2006; 101: 1900-20.
14. Holtmann G, Talley NJ, Liebregts T et al. A placebo-controlled trial of itopride in functional dyspepsia . N Engl J Med 2006; 354: 832-40.
15. Talley NJ, Tack J, Ptak T et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials . Gut 2008; 57: 740-6.
16. Veldhuyzen Van Zanten SJ . Pitfalls in designing trials of functional dyspepsia: the ascent and demise of itopride . Gut 2008; 57: 723-4.